Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and GVD With ctDNA-guided Consolidation in Relapsed or Refractory Classic Hodgkin Lymphoma
NCT07021989Phase 2Recruiting
- Start
- Aug 2026
- Primary completion
- Jul 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in classic Hodgkin lymphoma (cHL). Started Aug 2026; status: recruiting.
02
Drugs
03
Conditions
classic Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT07021989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07021989.